Cargando…

Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study

BACKGROUND: Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are frequently comorbid. AIMS: To assess the effectiveness of vortioxetine in patients with MDD and comorbid GAD. METHODS: Open-label, 8-week study (NCT04220996) in 100 adult outpatients with severe MDD and severe com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christensen, Michael Cronquist, Schmidt, Simon, Grande, Iria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112621/ https://www.ncbi.nlm.nih.gov/pubmed/35499104 http://dx.doi.org/10.1177/02698811221090627

Ejemplares similares

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study
por: Almeida, Susana S, et al.
Publicado: (2022)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
por: McIntyre, Roger S, et al.
Publicado: (2021)

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
por: Mattingly, Gregory W., et al.
Publicado: (2022)

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
por: Cumbo, Eduardo, et al.
Publicado: (2023)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study
por: Polosan, Mircea, et al.
Publicado: (2022)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study
por: De Filippis, Sergio, et al.
Publicado: (2022)

A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction
por: Keefe, Richard S E, et al.
Publicado: (2018)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
por: Ye, Xiaolin, et al.
Publicado: (2021)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
por: Segura-Garcia, Cristina, et al.
Publicado: (2021)

Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder
por: Zhou, Yongjie, et al.
Publicado: (2017)

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
por: Katona, Cornelius L, et al.
Publicado: (2014)

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
por: Kelliny, Marc, et al.
Publicado: (2015)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
por: Zhang, Xinyan, et al.
Publicado: (2022)

The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
por: Fu, Jie, et al.
Publicado: (2016)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
por: Papalexi, Eugenia, et al.
Publicado: (2022)

Gray Matter Abnormalities in Non-comorbid Medication-naive Patients with Major Depressive Disorder or Social Anxiety Disorder
por: Zhao, Youjin, et al.
Publicado: (2017)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
por: Inoue, Takeshi, et al.
Publicado: (2020)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
por: Basurte-Villamor, Ignacio, et al.
Publicado: (2022)

Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
por: Kotzalidis, Georgios D., et al.
Publicado: (2021)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
por: Xiong, Shihong, et al.
Publicado: (2022)

Neural temporal dynamics of stress in comorbid major depressive disorder and social anxiety disorder
por: Waugh, Christian E, et al.
Publicado: (2012)

Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
por: Chokka, Pratap, et al.
Publicado: (2021)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study
por: Vieta, Eduard, et al.
Publicado: (2019)

Disorder-specific cognitive profiles in major depressive disorder and generalized anxiety disorder
por: Hendriks, Sanne M, et al.
Publicado: (2014)

A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
por: Findling, Robert L., et al.
Publicado: (2018)

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
por: Mattingly, Gregory, et al.
Publicado: (2023)

Depressive comorbidity in preschool anxiety disorder
por: von Klitzing, Kai, et al.
Publicado: (2014)

The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis
por: Meeker, Amanda S, et al.
Publicado: (2015)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study
por: Kim, Hong, et al.
Publicado: (2021)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Differences in Perceptions of Major Depressive Disorder Symptoms and Treatment Priorities Between Patients and Health Care Providers Across the Acute, Post-Acute, and Remission Phases of Depression
por: Baune, Bernhard T., et al.
Publicado: (2019)

Exploring the clinical characteristics and etiological factors of comorbid major depressive disorder and social anxiety disorder
por: Berkol, Tonguc Demir, et al.
Publicado: (2023)

Generalized Anxiety Disorder, Comorbid Major Depression and Heart Rate Variability: A Case-Control Study in Taiwan
por: Chang, Hsin-An, et al.
Publicado: (2013)

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
por: Wang, Gang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m8pl8cdudb98805pdodm9trgbk